Physician profile
Bruce Mullen
NPI 1083781702
$21,587.72
in general payments reported to CMS, 2019-2025
26 companies · $4,653 in 2025
The $4,653 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,203 · 2020: $4,187 · 2021: $1,869 · 2022: $555 · 2023: $3,172 · 2024: $1,948 · 2025: $4,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,001 · Travel and Lodging: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,001.03 |
| Travel and Lodging | $3,772.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,958.63 | 2019-2025 | Eterna, Proclaim |
| Saluda Medical Americas, INC. | $5,875.83 | 2023-2025 | Evoke, Evoke Scs |
| Nevro Corp. | $2,785.11 | 2019-2021 | |
| Boston Scientific Corporation | $1,036.12 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Spr Therapeutics, INC | $671.17 | 2025 | Sprint Pns System |
| Medtronic, INC. | $583.38 | 2022-2025 | Intellis Adaptivestim |
| Stimwave Technologies Incorporated | $555.02 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $424.92 | 2019-2024 | Xtampza |
| Biodelivery Sciences International, INC. | $311.51 | 2019-2021 | |
| Pfizer INC. | $243.18 | 2019-2021 | |
| Si-Bone, INC. | $210.64 | 2023-2024 | |
| Curonix LLC | $166.06 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $150.24 | 2021-2025 | |
| Allergan, INC. | $122.85 | 2019 | |
| Eisai INC. | $114.96 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $80.04 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $69.37 | 2020-2021 | |
| Almatica Pharma LLC | $53.25 | 2022-2023 | Gralise |
| Amniox Medical, INC. | $43.91 | 2019 | |
| Painteq LLC | $34.86 | 2024 | Painteq |
| Bioventus LLC | $20.09 | 2021 | |
| Daiichi Sankyo INC. | $18.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.01 | 2025 | |
| Horizon Therapeutics Plc | $14.05 | 2020 | |
| Shionogi INC | $13.24 | 2019 | |
| Averitas Pharma INC. | $13.13 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.